Events & Presentations. The Investor Relations website contains information about Travere Therapeutics, Inc. 's business for stockholders, potential investors, and financial analysts. Prepared Remarks. Contact. The Investor Relations website contains information about PTC Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts. 03/28/2022. View Webcast. 1Q22 Supplemental Slides. 2.4 MB. 4634 M. 45°56′12.6″N. 04/19/2022. That's not a very high growth rate considering it doesn't make profits. JMIA. watertown, mass., may 16, 2022 (globe newswire) -- c4 therapeutics, inc. (c4t) (nasdaq: cccc), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced that the first patient has been dosed in … More events are coming soon. The Investor Relations website contains information about Vera Therapeutics's business for stockholders, potential investors, and financial analysts. Please note that any opinions, estimates, or forecasts regarding performance made by these analysts don't represent Inhibrx or its management team. Mar 7, 2022 10:30 AM EST. - Data from Ongoing CFT7455 Phase 1/2 Trial Presented at the American Association for Cancer Research (AACR) Annual Meeting; Enrollment Continues in Cohorts B1 and C - - Phase 1/2 Clinical Trial Initiated for CFT8634, a BRD9 Degrader, for Patients with Synovial Sarcoma and SMARCB1-null Solid Tumors - - Potential of TORPEDO® Platform Demonstrated at AACR with Pre-clinical . 1700 Owens Street, Suite 205 San Francisco, CA 94158. Mar 25, 2022. At Travere Therapeutics, our global team works with the rare disease community to identify, develop and deliver life-changing therapies. Listen to webcast. IR@Virios.com. Vertex Pharmaceuticals Fourth Quarter 2019 Earnings Conference Call. Jan 13, 2022. . Full-time, temporary, and part-time jobs. Transfer Agent. 24256790 73 open jobs for Senior director investor relations in Manchester. Find the latest C4 Therapeutics, Inc. (CCCC) stock quote, history, news and other vital information to help you with your stock trading and investing. Direct: 415-660-5320 Fax: 415-525-4200. info@nurix-inc.com Investors. Sema4 is transforming healthcare by applying artificial intelligence and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. View Presentation. Firm. 1700 Owens Street, Suite 205 San Francisco, CA 94158. Compounds derived from Shattuck's ARC platform simultaneously inhibit checkpoint molecules and activate costimulatory . Search and apply for the latest Investor relations jobs in Newton Center, MA. WATERTOWN, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation . 31, 2022-- DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2022 financial results after market close on Thursday, April 28, 2022 . If you experience any issues with this process, please contact us for further assistance. Mar 04, 2019. . Jan 10, 2022. watertown, mass., jan. 10, 2022 (globe newswire) -- c4 therapeutics, inc. (c4t) (nasdaq: cccc), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation. Biogen Analyst Q&A Call. 9.7 MB. Our lead asset is onvansertib, a PLK1 inhibitor that we are evaluating in combination with standard of care (SoC) therapeutics in clinical programs targeting indications such as KRAS-mutated metastatic . Sema4 Investor Deck- May 2022 8.2 MB Sema4's Mission Sema4 - Mission Video Watch on Events 04/25/2022. Financial Document Library. November 2, 2021. at 1:30 PM PDT. A global leader in DNA sequencing and array-based technologies, Illumina is fueling advancements in life sciences, oncology, reproductive health, genetic disease, agriculture, microbiology, and other emerging segments. . Media: LifeSci Communications, LLC Josephine Belluardo, Ph.D. 646-751-4361 jo@lifescicomms.com www.lifescicommunications.com. G1 Therapeutics, Inc. is a commercial stage oncology company focused on the development and commercialization of next generation therapies that improve the lives of those affected by cancer. . At Mirati Therapeutics Inc., we promise to treat your data with respect and will not share your information with any third party. October 18, 2021. at 10:00 AM PDT. Tango Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights 05.11.22. Delivering Value to Investors. View Presentation. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect . Webcast. LENSAR Inc. Fourth Quarter 2021 Financial Results Conference Call. Tango Therapeutics to Participate in the Guggenheim Synthetic Lethality Day 2022 05.09.22. Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and . March 11, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive Officer, will participate in a fireside chat at . 07°52′01.4″E Investor. Next Generation Cancer Therapies Our lead asset is onvansertib, a PLK1 inhibitor that we are evaluating in combination with standard of care (SoC) therapeutics in clinical programs targeting indications such as KRAS-mutated metastatic . Investors G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the discovery, development and delivery of next generation therapies that improve the lives of those affected by cancer, including the Company's first commercial product COSELA™ (trilaciclib). Targeted Protein Degradation. Quarterly Filing (10-Q/10-K) Transcript. Analyst Coverage. New York, NY 10004-1561. cstmail@continentalstock.com. ET on January 28, 2021 until 7:30 p.m. For more information, please visit www.c4therapeutics.com . The modest growth is probably largely reflected in the share. Supporting Materials. 2022. Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of cancer and autoimmune disease. NEW YORK -- (BUSINESS WIRE)--Feb. 17, 2022-- Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today reported that on February 14, 2022 , the company granted non-statutory stock options to purchase an aggregate. Sage Therapeutics Q4 2021 Financial Results Conference Call. J.P. Morgan 40th Annual Healthcare Conference. Past Events Date Event Details; Apr 28, 2022 at 5:30 PM EDT DexCom, Inc. First Quarter 2022 Earnings Release Conference Call. Investor Relations. . Dyne Therapeutics is building a leading muscle disease company dedicated to advancing innovative life-transforming therapeutics for people living with genetically driven diseases. We are dedicated to improving human health by unlocking the power of the genome. Investors Overview; News & Events . All investments involve risk, including possible loss of principal. Direct: 415-660-5320 Fax: 415-525-4200. info . C4 Therapeutics is registered under the ticker NASDAQ:CCCC . C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT8634, an Orally Bioavailable BiDAC™ Degrader for the Treatment of Synovial Sarcoma and SMARCB1-null Tumors; Trending News. SE. Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers. the purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of cft7455 administered orally in subjects with relapsed/refractory (r/r) non-hodgkin's lymphoma (nhl) or multiple myeloma (mm) administered according to different dosing schedules as a single agent and in combination … Read more. Our Opportunity C4 Therapeutics, Inc. (C4T) is searching for a Senior Manager of Investor Relations (IR) to become part of an expanding. LATEST NEWS TG Therapeutics to Participate in the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference. Direct: 415-660-5320 Fax: 415-525-4200. info@nurix-inc.com Our Opportunity: C4 Therapeutics, Inc. (C4T) is searching for an Associate Director of Investor Relations (IR) to become part of an expanding Communications and Investor Relations team. The company is discovering and developing novel cancer immunotherapies . Management will hold a conference call to review the company's first quarter 2022 performance. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer. Protagonist Therapeutics Reports Granting of Inducement Awards. Vera's mission is to advance treatments that target the . Listen to webcast. Novo Nordisk A/S Novo Allé 1 2880 Bagsværd Denmark +45-4444-8888 CVR-no. Merrill Robichaud Investor Relations Coordinator 978.932.0444 mrobichaud@insulet.com. Q4 2019 Presentation. Horizon Contacts: Tina Ventura Senior Vice President, Investor Relations Investor-relations . Free, fast and easy way find a job of 717.000+ postings in Newton Center, MA and other big cities in USA. Their latest funding was raised on Jun 14, 2021 from a Post-IPO Equity round. Biogen ADUHELM Launch. Investor Presentation. Investors: LifeSci Advisors, LLC Brian Ritchie 212-915-2578 britchie@lifesciadvisors.com www.lifesciadvisors.com. March 03, 2022. Search Senior director investor relations jobs in Manchester, NH with company ratings & salaries. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the 'unsubscribe' section below. The Investor Relations website contains information about Monte Rosa Therapeutics's business for stockholders, potential investors, and financial analysts. Our Opportunity: C4 Therapeutics, Inc. (C4T) is searching for an Associate Director of Investor Relations (IR) to become part of an expanding Communications and Investor Relations team. . Investor Relations. The Investor Relations website contains information about Dyne Therapeutics's business for stockholders, potential investors, and financial analysts. Analyst Coverage. Proxy Statement. Electronic trading poses unique risk to investors. Summary Toggle. Oct 22, 2019. Past performance of a security, market, or financial product does not guarantee future results. May 4, 2022 at 4:30 PM EDT. New York, NY 10004-1561. cstmail@continentalstock.com. Last Price Change Volume 52 Week High 52 Week Low Feb 16, 2022 8:00 AM EST. Corporate Overview. Learn more about our pipeline here. SVB Leerink 2022 Global Healthcare Conference. Protagonist Therapeutics Announces Appointment of Asif Ali as Executive Vice President and Chief Financial Officer. We are advancing a rich pipeline of investigational microbiome therapeutics designed to address a wide range of unmet medical needs, with a candidate in late-stage clinical development for recurrent C. difficile infection and candidates for inflammatory bowel disease and autism spectrum disorder in pre-clinical development.. The ideal candidate will help to proactively implement and manage C4T's investor relations program. C4 Therapeutics has raised a total of $423.8M in funding over 4 rounds. Skip to main navigation Monte Rosa. Fireside chat scheduled for Thursday, April 28, 2022 at 12:30 PM ET NEW YORK, April 26, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will participate in a fireside . Broadridge Corporate Issuer Solutions P.O. . Investor Contact Hannah Deresiewicz Stern Investor Relations, Inc. hannah . Overview; News & Events . Competitive salary. Supporting Materials. April 7, 2022. . Insulet Corporation 100 Nagog Park Acton, MA 01720. Candel's products are designed to improve survival while maintaining quality of life - from early- to late-stage disease. Investors & Media Home. Read more. watertown, mass., april 08, 2022 (globe newswire) -- c4 therapeutics, inc. (c4t) (nasdaq: cccc), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation. Webcast. Listen to webcast. Protagonist Therapeutics Announces Topline Data from Phase 2 IDEAL Study of PN-943 in Ulcerative Colitis. Cowen 42nd Annual Healthcare Conference. Pacific Biosciences of California, Inc. Third Quarter 2021 Earnings Conference Call. For more information, please visit www.c4therapeutics.com . Learn more Scorpion Therapeutics today announced the closing of an oversubscribed Series B financing, which raised $162 million. The ideal candidate will help to proactively implement and manage C4T's investor relations program. The Investor Relations website contains information about Prelude Therapeutics's business for stockholders, potential . Job email alerts. The Investor Relations website contains information about Olema Oncology's business for stockholders, potential investors, and financial analysts. To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. Overview. For more information, please visit www.c4therapeutics.com . Schrödinger First Quarter 2022 Financial Results Conference Call. Box 1342 Brentwood, NY 11717 T: 877-830-4936 . Vice President, Investor Relations 978.600.7717 dgordon@insulet.com ir@insulet.com. 11th Annual SVB Leerink Global Healthcare Conference. Documents. After submitting your request . Dyne Therapeutics is building a leading muscle disease company dedicated to advancing innovative life-transforming therapeutics for people living with genetically driven diseases. Verified employers. Jun 05, 2019. Biogen Planned Acquisition of Nightstar Therapeutics. Their stock opened with $19.00 in its Oct 1, 2020 IPO. Nurix Therapeutics Presents New Preclinical Data Supporting NX-2127 and DeTIL-0255 Clinical Programs at the American Association for Cancer Research Annual Meeting. Read more. 2.9 MB. . . For more information, please visit www.c4therapeutics.com . Virios Therapeutics (Nasdaq: VIRI) is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, such as fibromyalgia ("FM"). Our mission is powerful. Firm. C4 Therapeutics is funded by 23 investors. watertown, mass., april 08, 2022 (globe newswire) -- c4 therapeutics, inc. (c4t) (nasdaq: cccc), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation. Our Opportunity: C4 Therapeutics, Inc. (C4T) is searching for an Associate Director of Investor Relations (IR) to become part of an expanding Communications and Investor Relations team. Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers. Guardant Health is a leading precision oncology company focused on helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. Biogen ALS & R&D Portfolio Webcast Presentation. Below is a list of individuals that we're aware of that currently follow Inhibrx. (opens in new window) February 17, 2022. Biogen MS & R&D Webcast . watertown, mass., april 10, 2021 (globe newswire) -- c4 therapeutics, inc. (c4t) (nasdaq: cccc), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively. Rubius Therapeutics developed our proprietary RED PLATFORM® to generate red blood cells and genetically engineer them into a new class of cellular medicines, called Red Cell Therapeutics . SAN DIEGO -- (BUSINESS WIRE)--Mar. PacBio ASHG 2021 Workshop: Improving Human Health through Genomics with Highly Accurate Long Reads. Vera Therapeutics is a clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. 1700 Owens Street, Suite 205 San Francisco, CA 94158. The Investor Relations website contains information about Jounce Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts. Feb 23, 2022 at 10:15 AM EST . The Investor Relations website contains information about Dyne Therapeutics's business for stockholders, potential investors, and financial analysts. Upcoming Events. Click here for webcast. Skip to main navigation Toggle navigation Our goals are big. System response and access times may vary due to market conditions, system performance, and other factors. This process leads to a systemic, durable immune response against the tumor, with the potential to change disease outcomes across a variety of indications. Investors; Careers & Culture; Job Openings; Contact; Contact. View Webcast. The ideal candidate will help to proactively implement and manage C4T's investor relations program. . In the last year C4 Therapeutics saw its revenue grow by 13%. Below is a list of individuals that we're aware of that currently follow Inhibrx. Kymera is a clinical stage biopharmaceutical company developing novel protein degrader therapeutics to treat disease in powerful new ways, which harness the body's natural protein degradation system to selectively degrade disease causing proteins with the goal of completely removing them from the body. Conference and Other Investor Presentations. Sea Limited Reports First Quarter 2022 Results. Contact. Earnings Release. Pipeline. ET on February 4, 2021. . Investor Presentation. Lauren Paige Executive Assistant 978.600.7835 lpaige@insulet.com. Please note that any opinions, estimates, or forecasts regarding performance made by these analysts don't represent Inhibrx or its management team. The dial-in numbers for the conference call are (877) 212-6076 (Domestic) or (707) 287-9331 (International), passcode 7470222. Oct 30, 2019 at 5:00 PM EDT. Kymera is . Feb 24, 2022 8:00 AM EST. A replay of the conference call will be available starting at 7:30 p.m. The Investor Relations website contains information about Rubius Therapeutics's business for stockholders, potential investors, and financial analysts. Novavax will host a conference call today at 4:30pm ET. Relations. 01 Mar. Jounce Therapeutics is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer. Q1'2022 Earnings Slides 1.9 MB. Feb 18, 2022 at 9:20 AM EST. Investor Relations Corporate Profile Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. showing 1-3 of 3.